Promising Early Findings on First-of-its-Kind Retinitis Pigmentosa Therapy
Retinitis pigmentosa is a group of blinding eye diseases caused by more than 150 different gene mutations, making effective therapies difficult to develop. A new ...
Archive for News
7 Questions with Chief Ophthalmology Resident Dr. Grayson Armstrong
Grayson W. Armstrong, MD, MPH, chief resident of the Harvard Ophthalmology Residency Program and director of the Massachusetts Eye and Ear Ocular Trauma Service, gives ...
The Ugly Truth Behind Ear Candling
Have you thought about performing ear candling on yourself or your child to remove excess ear wax buildup? Dr. Cher (Xue) Zhao tells Focus that ...
New Book Featuring Mass. Eye and Ear Hearing Loss Experts Urges Sufferers to Seek Help
David Owen, a reporter for The New Yorker, spent time at Mass. Eye and Ear in 2018 interviewing hearing scientists, clinicians and patients for his ...
Sights Set on Summer at Camp Harbor View
Children receive vision screenings, eye health education from Mass. Eye and Ear at Camp Harbor View each summer. In July and August, staff from departments ...
10 Questions with Mass. Eye and Ear Otolaryngology Residency Program Director
Focus sat down with Program Director Dr. Stacey Gray to get the ins and outs of the Mass. Eye and Ear/Harvard Medical School Otolaryngology Residency ...
Researchers to Build Cell Atlas of the Human Eye as Part of International Collaboration
Chan Zuckerberg Initiative (CZI) awarded a $2 million grant to a team, including Mass. Eye and Ear ophthalmology scientists, as part of a global research ...
Online Health Fads to Avoid
In the new age of holistic healing and internet self-diagnosing, people are searching online to find natural remedies now more than ever. Most of the ...
Mission: Sight
On April 15, Sally Ankeny Reiley will run her sixth Boston Marathon® as a member of Team Eye and Ear, Mass. Eye and Ear’s marathon ...
Two Months After Gene Therapy, Jack Sees Brighter, More Clearly
Jack was born with an eye condition known as retinitis pigmentosa associated with RPE65 gene mutations. On March 20, 2018, he was treated with a newly FDA-approved gene therapy drug known as Luxturna — and the results are life-changing.
A Baby’s First Hearing Test — A Marathon Ahead
Technology to screen newborn babies for deafness has inspired Meagan to lace up her sneakers for the Boston Marathon in support of Massachusetts Eye and Ear.
Making Gene Therapy History
There's now an FDA-approved gene therapy drug for inherited blindness. Meet the first patient in the United States to receive it, Jack Hogan, and his care team from Mass. Eye and Ear.
